SFSebastian Fähndrich

Sebastian Fähndrich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sebastian Fähndrich has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET

    by F. C. Trudzinski, R. A. Jörres, P. Alter, K. Kahnert, B. Waschki, C. Herr, C. Kellerer, A. Omlor, C. F. Vogelmeier, S. Fähndrich, et al.

    We studied whether in patients with stable COPD blood gases (BG), especially oxygenated hemoglobin (OxyHem) as a novel biomarker confer information on disease burden and prognosis and how this adds to the information provided by the comorbidity pattern and systemic inflammation. Data from 2137 patients (GOLD grades 1–4) of the baseline dataset of the COSYCONET COPD cohort were used. The associations with dyspnea, exacerbation history, BODE-Index (cut-off ≤2) and all-cause mortality over 3 years of follow-up were determined by logistic and Cox regression analyses, with sex, age, BMI and pack years as covariates. Predictive values were evaluated by ROC curves. Capillary blood gases included SaO2, PaO2, PaCO2, pH, BE and the concentration of OxyHem [haemoglobin (Hb) x fractional SaO2, g/dL] as a simple-to-measure correlate of oxygen content. Inflammatory markers were WBC, CRP, IL-6 and -8, TNF-alpha and fibrinogen, and comorbidities comprised a broad panel including cardiac and metabolic disorders. Among BG, OxyHem was associated with dyspnoea, exacerbation history, BODE-Index and mortality. Among inflammatory markers and comorbidities, only WBC and heart failure were consistently related to all outcomes. ROC analyses indicated that OxyHem provided information of a magnitude comparable to that of WBC, with optimal cut-off values of 12.5 g/dL and 8000/µL, respectively. Regarding mortality, OxyHem also carried independent, additional information, showing a hazard ratio of 2.77 (95% CI: 1.85–4.15, p < 0.0001) for values 8000/µL was 2.33 (95% CI: 1.60–3.39, p < 0.0001). In stable COPD, the concentration of oxygenated hemoglobin provided additional information on disease state, especially mortality risk. OxyHem can be calculated from hemoglobin concentration and oxygen saturation without the need for the measurement of PaO2. It thus appears well suited for clinical use with minimal equipment, especially for GPs.


  • Influence of resting heart rate on chronic obstructive pulmonary disease

    by A Omlor, Fc Trudzinski, M Alqudrah, F Seiler, F Biertz, C Vogelmeier, T Welte, H Watz, B Waschki, Ra Jörres, et al.

    High resting heart rate (HR) has been shown to be associated with higher mortality in numerous diseases. In COPD, the association between resting HR and outcome is not well understood. The aim of the present study was to characterize the impact of HR on clinical outcomes. This study uses COX regression to investigate the influence of HR on the survival rate of 2741 COPD patients in the multicenter cohort study COSYCONET (German COPD and Systemic Consequences – Comorbidities Network). Patients with a HR > 72 beats per minute had a significantly (p < 0.05) higher all-cause mortality with an adjusted hazard ratio of 1.37 as compared to patients with a lower resting HR. When the two HR categories were formed based on time-updated HR, the adjusted hazard ratio for patients with a time-updated HR > 72 beats per minute was even highly significantly increased with a numeric value of 1.82. Linear regression models revealed a low FEV1, a low TLCO, a high ITGV, a history of hypertension and diabetes as well as a medication with SABAs and systemic steroids as factors that are associated with increased HR. In conclusion, an increased HR is associated with a higher mortality in patients with COPD. Pulmonary function, comorbidities and current medication are associated with increased HR. These results show that HR, especially time-updated HR, represents an independent predictor for mortality in COPD.

  • Alpha-1-Antitrypsin-Mangel: Pathophysiologie, Diagnostik und Therapie

    by Sebastian Fähndrich, Nikolas Bernhard, Philipp Lepper, Robert Bals

  • Open Access

    Cardiovascular risk in patients with alpha-1-antitrypsin deficiency

    by on behalf of the COSYCONET investigators, Sebastian Fähndrich, Frank Biertz, Annika Karch, Björn Kleibrink, Armin Koch, Helmut Teschler, Tobias Welte, Hans-Ulrich Kauczor, Sabina Janciauskiene, et al.

    Alpha-1-antitrypsin deficiency (AATD) is a rare inherited condition caused by mutations of the SERPINA1 gene that is associated with the development of a COPD like lung disease. The comorbidities in patients with AATD-related lung diseases are not well defined. The aim of this study was to analyze the clinical phenotype of AATD patients within the German COPD cohort study COSYCONET (“COPD and SYstemic consequences-COmorbidities NETwork”) cohort focusing on the distribution of comorbidities. The data from 2645 COSYCONET patients, including 139 AATD patients (110 with and 29 without augmentation therapy), were analyzed by descriptive statistics and regression analyses. We found significantly lower prevalence of cardiovascular comorbidities in AATD patients as compared to non-AATD COPD patients. After correction for age, pack years, body mass index, and sex, the differences were still significant for coronary artery disease (p = 0.002) and the prevalence of peripheral artery disease as determined by an ankle-brachial-index <= 0.9 (p = 0.035). Also the distribution of other comorbidities such as bronchiectasis differed between AATD and non-deficient COPD. AATD is associated with a lower prevalence of cardiovascular disease, the underlying mechanisms need further investigation.


  • Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ

    by Nikolas Bernhard, Philipp M. Lepper, Claus Vogelmeier, Martina Seibert, Stefan Wagenpfeil, Robert Bals, Sebastian Fähndrich


  • The presence and impact of chronic kidney disease in COPD patients, data from the German COSYCONET cohort

    by Mohammad Alqudrah, Franziska Trudzinski, Frederik Seiler, Franz Biertz, Armin Koch, Claus Vogelmeier, Tobias Welte, Henrik Watz, Sebastian Fähndrich, Robert Bals, et al.

    Introduction: The prognosis of COPD patients is compromised by different comorbidities. There are only few data concerning chronic kidney disease (CKD) in these patients. We therefore analyzed CKD patients in the German COSYCONET cohort. Methods: CKD was defined by an eGFR < 60mL/min/1.73m2 at 2 visits. The association of CKD with functional, laboratory values and other comorbidities were analyzed using group comparisons and a multivariate binary logistic regression. Results: 2140 patients (60.7 % male) were analyzed, 161 (7.5 %) had CKD. There were no differences in gender distribution or pack years. CKD patients were older (72.24 ± 6.60 versus 64.09 ± 8.27 y) and showed higher FEV1 (61.04 ± 17.7 %pred versus 57.56 ± 21.2 %pred p = 0.019), less ITGV %pred (132.1 ± 34.83 vs. 143.73 ± 37.42 p < .001). Hemoglobin, pO2 and SaO2 were reduced. They showed a higher prevalence of cardiovascular disease (CVD) as coronary artery disease (25.2% versus 14.0 % P 0.002) myocardial infarction (12.9 versus 7.4% p= 0.013) heart failure (22.40 versus 8.50% P < 0.0001) arrhythmias (36.8 % versus 14.9 % P= < 0.0001) peripheral vascular disease (18.71 %versus 10.10% P= 0.0008) hypertension (74.20 % versus 53.20 P < 0.0001) and stroke (7.70 versus 3.90%, P 0.0197). Multivariate analysis adjusted for age gender and BMI revealed a significant reduction for TLCO % pred. in CKD patients, no difference where shown for % predicted in FEV1, FVC, sRaweff and ITGV. But CKD patients had lower hemoglobin, a higher prevalence of hypertension, lower distances in 6-MWT and higher MRC values. Conclusion: COPD patients with CKD should receive special attention to detect other comorbidities.

  • Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency

    by Sebastian Fähndrich, Nikolas Bernhard, Philipp M. Lepper, Claus Vogelmeier, Martina Seibert, Stefan Wagenpfeil, Robert Bals


  • Open Access

    Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency – analysis from the German Registry

    by Nikolas Bernhard, Philipp M. Lepper, Claus Vogelmeier, Martina Seibert, Stefan Wagenpfeil, Robert Bals, Sebastian Fähndrich

    Background: Alpha-1-antitrypsin deficiency (AATD) is a rare hereditary disease that is associated with a higher risk to develop chronic obstructive pulmonary disease and liver cirrhosis. Previous cross-sectional studies on AATD individuals have shown a relationship between worse St George’s Respiratory Questionnaire (SGRQ) scores and elevated exacerbation rate or high cigarette consumption. There is a lack of longitudinal data on the relationship between the exacerbation rate and worsening of SGRQ during disease. The aim of this study was to provide not only cross-sectional data but also information about the deterioration in quality of life over a follow-up period up to 7 years (median follow-up period of 3.33 years). Methods: We investigated questionnaire-based data of the German AATD registry concerning the relationship between SGRQ and exacerbation frequency, smoking history, forced expiratory volume in 1 second (FEV1) and carbon monoxide diffusion capacity (DLCO) first in cross-sectional analysis and later in longitudinal analysis. Results: Eight hundred sixty-eight individuals with protease inhibitor ZZ (PiZZ) genotype with an average age of 52.6±12.8 years had an SGRQ score of 45.7±20.6. SGRQ significantly correlated with the exacerbation frequency within the last 2 years (r=0.464; Pr=0.233; P1 (r=−0.436; Pr=−0.333; Pr=0.292; PPr=0.144; P=0.015). Conclusion: Worsening of SGRQ is associated with the exacerbation frequency in individuals with PiZZ AATD.


  • Alpha-1-Antitrypsin-Mangel rechtzeitig erkennen und behandeln

    by Sebastian Fähndrich, Nikolas Bernhard, Philipp Lepper, Robert Bals

  • Open Access

    Runtime and aPTT predict venous thrombosis and thromboembolism in patients on extracorporeal membrane oxygenation: a retrospective analysis

    by Franziska C. Trudzinski, Peter Minko, Daniel Rapp, Sebastian Fähndrich, Hendrik Haake, Myriam Haab, Rainer M. Bohle, Monika Flaig, Franziska Kaestner, Robert Bals, et al.